Quality of life in patients with thyroid cancer
Author: Hedman, Christel
Date: 2017-11-24
Location: Magnus Huss aula, Stockholms sjukhem, Mariebergsgatan 22, Stockholm
Time: 09.00
Department: Inst för molekylär medicin och kirurgi / Dept of Molecular Medicine and Surgery
View/ Open:
Thesis (588.0Kb)
Abstract
Background: The prevalence of differentiated thyroid cancer (DTC) is increasing as a consequence of rising incidence, young age at diagnosis and excellent survival. The established treatment is surgery, followed by radioiodine as well as levothyroxine substitution. Because of the longevity of DTC patients, health-related quality of life (HRQoL) has become important. Previous studies have shown decreased HRQoL in DTC, nevertheless, changes of HRQoL over time and factors affecting HRQoL are scarcely described. The aims of this thesis were to investigate long-term HRQoL, how HRQoL changes over time and how anxiety and fear of recurrence affect patients with thyroid cancer.
Patients, methods and results: In Studies I-III, SF-36 and a study-specific questionnaire were used. In Studies I-II, long-term HRQoL was measured by including patients 14-17 years after diagnosis. HRQoL was shown to be lower in DTC patients compared with the Swedish general population. Half of the patients had fear of recurrence, and those with fear had significantly lower HRQoL. Thyroid-related symptoms, such as fatigue, sleeping problems, irritability and sweating were measured, and the majority (88%) had at least one of these symptoms. Those with major or moderate symptom intensity had significantly lower HRQoL in eight and four SF-36 domains, respectively. These differences remained after adjustment for age, sex, comorbidities and education.
In study III, DTC patients were included at diagnosis and followed-up. After one year, HRQoL was higher compared with baseline in six of eight SF-36 domains. As the majority of the patients were treated with levothyroxine in TSH suppressive doses, this might have affected HRQoL. Surprisingly, those on moderate TSH suppression had lower HRQoL compared with those on complete suppression. In addition, more than half of the patients had a fear of recurrence, with significantly lower HRQoL. Predictive factors of HRQoL at follow-up were studied and in bivariate models, e.g. comorbidities and HRQoL at diagnosis were associated with lower HRQoL at one year. In regression models, poor HRQoL at diagnosis was the only predictive factor for poor HRQoL at one-year of follow-up, after adjustment for comorbidities, age, sex, stage of disease and fear of recurrence.
To broaden the understanding about anxiety and fear of recurrence, semi-structured interviews were performed with 21 patients in Study IV. Anxiety was present both in patients with and without recurrence and regardless of sociodemographic factors. Fear of recurrence, follow-up routines, distrust in the healthcare system and lack of information were all sources of anxiety. In some patients, hidden anxiety not mentioned in the beginning became apparent later during the interviews. Everyday life and routines were used as protective strategies against frightening thoughts. Avoiding contact with healthcare helped them gather energy to cope with their disease.
Discussion: HRQoL was decreased in DTC patients compared with a general population and was negatively associated with thyroid-related symptoms and fear of recurrence. Interestingly, TSH suppression was not associated to lower HRQoL. The patients’ perception of having a “good cancer” might have discouraged them from discussing anxiety with healthcare. As HRQoL at diagnosis was the only independent predictive factor of HRQoL at one year of follow-up, the evaluation of HRQoL early in the disease trajectory is important. Individualised follow-up routines and evaluation of fears and anxiety during consultations might be helpful, and instead of using the term “good cancer”, “low-risk cancer” can be recommended.
Patients, methods and results: In Studies I-III, SF-36 and a study-specific questionnaire were used. In Studies I-II, long-term HRQoL was measured by including patients 14-17 years after diagnosis. HRQoL was shown to be lower in DTC patients compared with the Swedish general population. Half of the patients had fear of recurrence, and those with fear had significantly lower HRQoL. Thyroid-related symptoms, such as fatigue, sleeping problems, irritability and sweating were measured, and the majority (88%) had at least one of these symptoms. Those with major or moderate symptom intensity had significantly lower HRQoL in eight and four SF-36 domains, respectively. These differences remained after adjustment for age, sex, comorbidities and education.
In study III, DTC patients were included at diagnosis and followed-up. After one year, HRQoL was higher compared with baseline in six of eight SF-36 domains. As the majority of the patients were treated with levothyroxine in TSH suppressive doses, this might have affected HRQoL. Surprisingly, those on moderate TSH suppression had lower HRQoL compared with those on complete suppression. In addition, more than half of the patients had a fear of recurrence, with significantly lower HRQoL. Predictive factors of HRQoL at follow-up were studied and in bivariate models, e.g. comorbidities and HRQoL at diagnosis were associated with lower HRQoL at one year. In regression models, poor HRQoL at diagnosis was the only predictive factor for poor HRQoL at one-year of follow-up, after adjustment for comorbidities, age, sex, stage of disease and fear of recurrence.
To broaden the understanding about anxiety and fear of recurrence, semi-structured interviews were performed with 21 patients in Study IV. Anxiety was present both in patients with and without recurrence and regardless of sociodemographic factors. Fear of recurrence, follow-up routines, distrust in the healthcare system and lack of information were all sources of anxiety. In some patients, hidden anxiety not mentioned in the beginning became apparent later during the interviews. Everyday life and routines were used as protective strategies against frightening thoughts. Avoiding contact with healthcare helped them gather energy to cope with their disease.
Discussion: HRQoL was decreased in DTC patients compared with a general population and was negatively associated with thyroid-related symptoms and fear of recurrence. Interestingly, TSH suppression was not associated to lower HRQoL. The patients’ perception of having a “good cancer” might have discouraged them from discussing anxiety with healthcare. As HRQoL at diagnosis was the only independent predictive factor of HRQoL at one year of follow-up, the evaluation of HRQoL early in the disease trajectory is important. Individualised follow-up routines and evaluation of fears and anxiety during consultations might be helpful, and instead of using the term “good cancer”, “low-risk cancer” can be recommended.
List of papers:
I. Hedman C, Djärv T, Strang P, Lundgren CI. Determinants of long-term quality of life in patients with differentiated thyroid carcinoma - a population-based cohort study in Sweden. Acta Oncologica. 2016;55(3):365-9.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Hedman C, Djärv T, Strang P, Lundgren CI. Effect of thyroid-related symptoms on long-term quality of life in patients with differentiated thyroid carcinoma: a population-based study in Sweden. Thyroid. 2017 Aug;27(8):1034-1042.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Hedman C, Djärv T, Strang P, Lundgren CI. Fear of recurrence and view of life affect health-related quality of life in patients with differentiated thyroid carcinoma: a prospective Swedish population-based study. [Manuscript]
IV. Hedman C, Djärv T, Widberg I, Strang P, Lundgren CI. Anxiety and fear of recurrence despite a good prognosis: an interview study with differentiated thyroid cancer patients. Thyroid. 2017 Sep 6.
Fulltext (DOI)
Pubmed
I. Hedman C, Djärv T, Strang P, Lundgren CI. Determinants of long-term quality of life in patients with differentiated thyroid carcinoma - a population-based cohort study in Sweden. Acta Oncologica. 2016;55(3):365-9.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Hedman C, Djärv T, Strang P, Lundgren CI. Effect of thyroid-related symptoms on long-term quality of life in patients with differentiated thyroid carcinoma: a population-based study in Sweden. Thyroid. 2017 Aug;27(8):1034-1042.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Hedman C, Djärv T, Strang P, Lundgren CI. Fear of recurrence and view of life affect health-related quality of life in patients with differentiated thyroid carcinoma: a prospective Swedish population-based study. [Manuscript]
IV. Hedman C, Djärv T, Widberg I, Strang P, Lundgren CI. Anxiety and fear of recurrence despite a good prognosis: an interview study with differentiated thyroid cancer patients. Thyroid. 2017 Sep 6.
Fulltext (DOI)
Pubmed
Institution: Karolinska Institutet
Supervisor: Ihre Lundgren, Catharina
Co-supervisor: Strang, Peter; Djärv, Therese
Issue date: 2017-11-02
Rights:
Publication year: 2017
ISBN: 978-91-7676-813-6
Statistics
Total Visits
Views | |
---|---|
Quality ...(legacy) | 561 |
Quality ... | 304 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Quality ... | 2 | 2 | 1 | 2 | 2 | 1 | 3 |
File Visits
Views | |
---|---|
Thesis_Christel_Hedman.pdf(legacy) | 1501 |
Thesis_Christel_Hedman.pdf | 928 |
Top country views
Views | |
---|---|
Sweden | 184 |
United States | 169 |
China | 43 |
Germany | 39 |
Japan | 30 |
South Korea | 18 |
Austria | 15 |
Turkey | 14 |
Russia | 12 |
Saudi Arabia | 12 |
Top cities views
Views | |
---|---|
Ashburn | 47 |
Lane | 28 |
Woodbridge | 24 |
Beijing | 19 |
Stockholm | 18 |
Vienna | 15 |
Wilmington | 15 |
Houston | 13 |
Seoul | 10 |
Dammam | 9 |